Menu Close

Publications

Peer-reviewed publications

  • Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers
    Pizzato HA, Alonso-Guallart P, Woods J, Johannesson B, Connelly JP, Fehniger TA, Atkinson JP, Pruett-Miller SM, Monsma FJ, Bhattacharya D
    bioRxiv 2023 Jun 29:20230627546594
  • T-BET and EOMES Sustain Mature Human NK Cell Identity and Antitumor Function
    Wong P, Foltz JA, Chang L, Neal CC, Yao T, Cubitt CC, Tran J, Kersting-Schadek S, Palakurty S, Jaeger N, Russler-Germain DA, Marin ND, Gang M, Wagner JA, Zhou AY, Jacobs MT, Foster M, Schappe T, Marsala L, McClain E, Pence P, Becker-Hapak M, Fisk B, Petti AA, Griffith OL, Griffith M, Berrien-Elliott MM, Fehniger TA
    J Clin Invest 2023 Jul 3;133(13):e162530
  • Anti-Myeloma Efficacy of CAR-INKT Is Enhanced With a Long-Acting IL-7, RhIL-7hyFc
    O’Neal J, Cooper ML, Ritchey JK, Gladney SW, Niswonger J, Gonzalez LS, Street E, Haas GJ, Carter AJ, Amayta PN, Gao F, Lee BH, Choi D, Berrien-Elliott MM, Zhou AY, Fehniger TA, Rettig MP, DiPersio JF
    Blood Adv 2023 Jul 3:bloodadvances2023010032; [ahead of print]
  • Costimulatory Domains Direct Distinct Fates of CAR-Driven T-Cell Dysfunction
    Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu YS, Chang TC, Chang J, Warrington J, Ha H, Kingston N, Hogg G, Slade M, Berrien-Elliott MM, Foster M, Kersting-Schadek S, Gruszczynska A, DeNardo D, Fehniger TA, Artyomov M, Singh N
    Blood 2023 Jun 29;141(26):3153-3165
  • Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies
    Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Shah NM, Kahl BS
    Clin Lymphoma Myeloma Leuk 2023 Jul;23(7):552-560
  • Immunotherapeutic Approach to Reduce Senescent Cells and Alleviate Senescence-Associated Secretory Phenotype in Mice
    Shrestha N, Chaturvedi P, Zhu X, Dee MJ, George V, Janney C, Egan JO, Liu B, Foster M, Marsala L, Wong P, Cubitt CC, Foltz JA, Tran J, Schappe T, Hsiao K, Leclerc GM, You L, Echeverri C, Spanoudis C, Carvalho A, Kanakaraj L, Gilkes C, Encalada N, Kong L, Wang M, Fang B, Wang Z, Jiao JA, Muniz GJ, Jeng EK, Valdivieso N, Li L, Deth R, Berrien-Elliott MM, Fehniger TA, Rhode PR, Wong HC
    Aging Cell 2023 May;22(5):e13806
  • Computational Prediction of MHC Anchor Locations Guides Neoantigen Identification and Prioritization
    Xia H, McMichael J, Becker-Hapak M, Onyeador OC, Buchli R, McClain E, Pence P, Supabphol S, Richters MM, Basu A, Ramirez CA, Puig-Saus C, Cotto KC, Freshour SL, Hundal J, Kiwala S, Goedegebuure SP, Johanns TM, Dunn GP, Ribas A, Miller CA, Gillanders WE, Fehniger TA, Griffith OL, Griffith M
    Sci Immunol 2023 Apr 14;8(82):eabg2200
  • Allogeneic Natural Killer Cell Therapy
    Berrien-Elliott MM, Jacobs MT, Fehniger TA
    Blood 2023 Feb 23;141(8):856-868
  • Costimulatory Domains Direct Distinct Fates of CAR-Driven T Cell Dysfunction
    Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu YS, Chang TC, Chang J, Warrington J, Ha H, Kingston N, Hogg G, Slade M, Berrien-Elliot MM, Foster M, Kersting-Schadek S, Gruszczynska A, DeNardo D, Fehniger TA, Artyomov M, Singh N
    bioRxiv 2023 Jan 27:20230126525725
  • Enrichment of Innate Immune Cells From PBMC Followed by Triple Cytokine Activation for Adoptive Immunotherapy
    Al-Kadhimi Z, Callahan M, Fehniger T, Cole KE, Vose J, Hinrichs S
    Int Immunopharmacol 2022 Dec;113(Pt A):109387
  • Metabolic Biomarkers Assessed With PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients With Diffuse Large B-Cell Lymphoma
    Jaswal S, Sanders V, Pullarkat P, Teja S, Salter A, Watkins MP, Atagu N, Ludwig DR, Mhlanga J, Mellnick VM, Peterson LR, Bartlett NL, Kahl BS, Fehniger TA, Ghobadi A, Cashen AF, Mehta-Shah N, Ippolito JE
    Cancers (Basel) 2022 Jun 14;14(12):2932
  • Phase 1/Dose Expansion Trial of Brentuximab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL
    Blood 2022 Mar 31;139(13):1999-2010
  • Donor Memory-Like NK Cells Persist and Induce Remissions in Pediatric Patients With Relapsed AML After Transplant
    Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, Foster M, Schappe T, McClain E, Pence PP, Desai S, Kersting-Schadek S, Wong P, Russler-Germain DA, Fisk B, Lie WR, Eisele J, Hyde S, Bhatt ST, Griffith OL, Griffith M, Petti AA, Cashen AF, Fehniger TA
    Blood 2022 Mar 17;139(11):1670-1683
  • A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells.
    Cubitt CC, McClain E, Becker-Hapak M, Foltz JA, Wong P, Wagner JA, Neal CC, Marin ND, Marsala L, Foster M, Schappe T, Soon-Shiong P, Lee J, Berrien-Elliott MM, Fehniger TA. Mol Ther Oncolytics. 2022 Feb 15;24:585-596. doi: 10.1016/j.omto.2022.02.009. 
  • Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
    Berrien-Elliott MM, Foltz JA, Russler-Germain DA, Neal CC, Tran J, Gang M, Wong P, Fisk B, Cubitt CC, Marin ND, Zhou AY, Jacobs MT, Foster M, Schappe T, McClain E, Kersting-Schadek S, Desai S, Pence P, Becker-Hapak M, Eisele J, Mosior M, Marsala L, Griffith OL, Griffith M, Khan SM, Spencer DH, DiPersio JF, Romee R, Uy GL, Abboud CN, Ghobadi A, Westervelt P, Stockerl-Goldstein K, Schroeder MA, Wan F, Lie WR, Soon-Shiong P, Petti AA, Cashen AF, Fehniger TA. Sci Transl Med. 2022 Feb 23;14(633):eabm1375. doi: 10.1126/scitranslmed.abm1375. 
  • Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
    Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, Foster M, Schappe T, McClain E, Pence PP, Desai S, Kersting-Schadek S, Wong P, Russler-Germain DA, Fisk B, Lie WR, Eisele J, Hyde S, Bhatt ST, Griffith OL, Griffith M, Petti AA, Cashen AF, Fehniger TA. Blood. 2022 Mar 17;139(11):1670-1683. doi: 10.1182/blood.2021013972.
  • Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
    Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Blood. 2022 Feb 24;139(8):1177-1183. doi: 10.1182/blood.2021011532.
  • Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
    Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL. Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894.
  • CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
    Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, DiPersio JF.JCI Insight. 2021 Aug 23;6(16):e149819. doi: 10.1172/jci.insight.149819.
  • A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.
    Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, Desai S, Neal CC, Pence P, Wong P, Wagner JA, Russler-Germain DA, Zhu X, Spanoudis CM, Gallo VL, Echeverri CA, Ramirez LL, You L, Egan JO, Rhode PR, Jiao JA, Muniz GJ, Jeng EK, Prendes CA, Sullivan RP, Berrien-Elliott MM, Wong HC, Fehniger TA. Cancer Immunol Res. 2021 Sep;9(9):1071-1087. doi: 10.1158/2326-6066.CIR-20-1002.
  • Memory-like Differentiation Enhances NK Cell Responses to Melanoma.
    Marin ND, Krasnick BA, Becker-Hapak M, Conant L, Goedegebuure SP, Berrien-Elliott MM, Robbins KJ, Foltz JA, Foster M, Wong P, Cubitt CC, Tran J, Wetzel CB, Jacobs M, Zhou AY, Russler-Germain D, Marsala L, Schappe T, Fields RC, Fehniger TA. Clin Cancer Res. 2021 Sep 1;27(17):4859-4869. doi: 10.1158/1078-0432.CCR-21-0851. 
  • Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion.
    Mah-Som AY, Keppel MP, Tobin JM, Kolicheski A, Saucier N, Sexl V, French AR, Wagner JA, Fehniger TA, Cooper MA.
    Cell Rep. 2021 Jun 1;35(9):109209. doi: 10.1016/j.celrep.2021.109209
  • Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.
    Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K.
    Clin Cancer Res. 2021 May 13. doi: 10.1158/1078-0432.CCR-21-0164. 
  • Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
    Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA.
    Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. 
  • Flow cytometry-based ex vivo murine NK cell cytotoxicity assay.
    Wong P, Wagner JA, Berrien-Elliott MM, Schappe T, Fehniger TA.
    STAR Protoc. 2021 Jan 12;2(1):100262. doi: 10.1016/j.xpro.2020.100262. 
  • Memory-like natural killer cells for cancer immunotherapy.
    Gang M, Wong P, Berrien-Elliott MM, Fehniger TA.

    Semin Hematol. 2020 Oct;57(4):185-193. doi: 10.1053/j.seminhematol.2020.11.003. Epub 2020 Nov 17

  • A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, Dipersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA.
    Biol Blood Marrow Transplant. 2020 Dec;26(12):2223-2228. doi: 10.1016/j.bbmt.2020.08.017. 
  • Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia.
    Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Srivatsan SN, Gao F, Romee R, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio J, Fehniger TA.
    Cancer Discov. 2020 Dec;10(12):1854-1871. doi: 10.1158/2159-8290.CD-20-0312.
  • CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA.
    Blood. 2020 Nov 12;136(20):2308-2318. doi: 10.1182/blood.2020006619
  • CD56 regulates human NK cell cytotoxicity through Pyk2.
    Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott MM, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM.
    Elife. 2020 Jun 8;9:e57346. doi: 10.7554/eLife.57346.
  • Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity.
    Wagner JA, Wong P, Schappe T, Berrien-Elliott MM, Cubitt C, Jaeger N, Lee M, Keppel CR, Marin ND, Foltz JA, Marsala L, Neal CC, Sullivan RP, Schneider SE, Keppel MP, Saucier N, Cooper MA, Fehniger TA.
    Cell Rep. 2020 Jun 2;31(9):107720. doi: 10.1016/j.celrep.2020.107720.
  • Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.
    Oza A, Rettig MP, Powell P, O’Brien K, Clifford DB, Ritchey J, Gehrs L, Hollaway J, Major E, Fehniger TA, Miller CA, Soon-Shiong P, Rock A, DiPersio JF.

    Blood Adv. 2020 Jun 9;4(11):2387-2391. doi: 10.1182/bloodadvances.2019000664.

  • Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development.
    Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, Wagner JA, Kingsley PD, McGrath KE, Fehniger TA, Palis J, Sturgeon CM.

    Dev Cell. 2020 Apr 20;53(2):229-239.e7. doi: 10.1016/j.devcel.2020.02.016. Epub 2020 Mar 19.

  • Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis.
    Mack MR, Brestoff JR, Berrien-Elliott MM, Trier AM, Yang TB, McCullen M, Collins PL, Niu H, Bodet ND, Wagner JA, Park E, Xu AZ, Wang F, Chibnall R, Council ML, Heffington C, Kreisel F, Margolis DJ, Sheinbein D, Lovato P, Vivier E, Cella M, Colonna M, Yokoyama WM, Oltz EM, Fehniger TA, Kim BS.

    Sci Transl Med. 2020 Feb 26;12(532):eaay1005. doi: 10.1126/scitranslmed.aay1005.

  • KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
    Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS.Blood Adv. 2020 Feb 25;4(4):740-754. doi: 10.1182/bloodadvances.2019001053.
  • Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes.
    Barnell EK, Waalkes A, Mosior MC, Penewit K, Cotto KC, Danos AM, Sheta LM, Campbell KM, Krysiak K, Rieke D, Spies NC, Skidmore ZL, Pritchard CC, Fehniger TA, Uppaluri R, Govindan R, Griffith M, Salipante SJ, Griffith OL.
    JCO Clin Cancer Inform. 2019 Oct;3:1-12. doi: 10.1200/CCI.19.00077.                    
  • MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells.
    Berrien-Elliott MM, Sun Y, Neal C, Ireland A, Trissal MC, Sullivan RP, Wagner JA, Leong JW, Wong P, Mah-Som AY, Wong TN, Schappe T, Keppel CR, Cortez VS, Stamatiades EG, Li MO, Colonna M, Link DC, French AR, Cooper MA, Wang WL, Boldin MP, Reddy P, Fehniger TA. 

    Immunity. 2019 Sep 17;51(3):479-490.e6. doi: 10.1016/j.immuni.2019.06.016. Epub 2019 Aug 8.

  • Glycolytic Requirement for NK Cell Cytotoxicity and Cytomegalovirus Control
    Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA
    JCI Insight 2017 Dec 7;2(23)
  • A Deep Learning Approach to Automate Refinement of Somatic Variant Calling From Cancer Sequencing Data
    Ainscough BJ, Barnell EK, Ronning P, Campbell KM, Wagner AH, Fehniger TA, Dunn GP, Uppaluri R, Govindan R, Rohan TE, Griffith M, Mardis ER, Swamidass SJ, Griffith OL
    Nat Genet 2018 Dec;50(12):1735-1743
  • Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory
    Cooper MA, Fehniger TA, Colonna M
    Cold Spring Harb Perspect Biol 2018 Oct 1;10(10)
  • A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients With High-Risk Acute Myeloid Leukemia
    Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E
    Biol Blood Marrow Transplant 2018 Aug;24(8):1581-1589
  • Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2018 Feb;59(2):357-362
  • Lenalidomide Consolidation Benefits Patients With CLL Receiving Chemoimmunotherapy: Results for CALGB 10404 (Alliance)
    Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA
    Blood Adv 2018 Jul 24;2(14):1705-1718
  • Comment On: Evidence of Innate Lymphoid Cell Redundancy in Humans
    Orange JS, Mace EM, French AR, Yokoyama WM, Fehniger TA, Cooper MA
    Nat Immunol 2018 Aug;19(8):788-789
  • miR142 Loss-Of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis
    Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley TJ, Maillard I, Reddy PR, Link DC
    Cancer Res 2018 Jul 1;78(13):3510-3521
  • First-In-Human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation
    Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA,** Miller JS**   **Co-Senior authors
    Blood 2018 Jun 7;131(23):2515-2527
  • Lenalidomide Results in a Durable Complete Remission in Acute Myeloid Leukemia Accompanied by Persistence of Somatic Mutations and a T-Cell Infiltrate in the Bone Marrow
    Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA
    Haematologica 2018 Jun;103(6):e270-e273
  • A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients With High-Risk Acute Myeloid Leukemia
    Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E
    Biol Blood Marrow Transplant 2018 Mar 26; [Epub ahead of print]
  • Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial
    Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA
    Blood 2018 Jan 11;131(2):182-190
  • Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory
    Cooper MA, Fehniger TA, Colonna M
    Cold Spring Harb Perspect Biol 2017 Dec 18; [Epub ahead of print]
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Glycolytic Requirement for NK Cell Cytotoxicity and Cytomegalovirus Control
    Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA
    JCI Insight 2017 Dec 7;2(23); [Epub ahead of print]
  • CD56bright NK Cells Exhibit Potent Antitumor Responses Following IL-15 Priming
    Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA
    J Clin Invest 2017 Nov 1;127(11):4042-4058
  • Guidelines for the use of flow cytometry and cell sorting in immunological studies.  Cossarizza A … Fehniger TA …Zimmermann J [100 Authors].  Eur J Immunol. 2017 Oct;47(10):158401797
  • Minimal Activity of Nanoparticle Albumin-Bound (Nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2018 Feb;59(2):357-362
  • A phase I/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma
    Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
    Clin Lymphoma Myeloma Leuk 2017 Jun;17(6):347-353
  • Transcriptional and post-transcriptional regulation of NK cell development and function
    Leong JW, Wagner JA, Ireland AR, Fehniger TA
    Clin Immunol 2017 Apr;177:60-69
  • Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans
    Xiao DY, Luo S, O’Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Cytokine-induced memory-like differentiation enhances unlicensed natural killer cell antileukemia and FcgammaRIIIa-triggered responses
    Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA
    Biol Blood Marrow Transplant 2017 Mar;23(3):398-404
  • Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Harnessing NK cell memory for cancer immunotherapy [Review]
    Fehniger TA, Cooper MA
    Trends Immunol 2016 Oct 20; [Epub ahead of print]
  • Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis
    Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L
    Acta Neuropathol 2016 Oct 4; [Epub ahead of print]
  • Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Jul 21; [Epub ahead of print]
  • Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • Transcriptional and post-transcriptional regulation of NK cell development and function
    Leong JW, Wagner JA, Ireland AR, Fehniger TA
    Clin Immunol 2016 Mar 3; [Epub ahead of print]
  • The IL-15-based ALT-803 complex enhances FcgRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
    Rosario M, Liu B, Kong L, Collins L, Schneider SE, Chen X, Han KP, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell B, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms D, Cashen A, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2015 Sep 30; [Epub ahead of print]
  • Improving natural killer cell cancer immunotherapy
    Berrien-Elliott MM, Romee R, Fehniger TA
    Curr Opin Organ Transplant 2015 Sep 25; [Epub ahead of print]
  • MicroRNA-15/16 antagonizes Myb to control NK cell maturation
    Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA
    J Immunol 2015 Sep 15;195(6):2806-17
  • Human cytokine-induced memory-like natural killer cells
    Berrien-Elliott MM, Wagner JA, Fehniger TA
    J Innate Immun 2015 Apr 30; [Epub ahead of print]
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • PTEN regulates natural killer cell trafficking in vivo
    Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA
    Proc Natl Acad Sci U S A 2015 Feb 17;112(7):E700-9
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O’Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • MicroRNA management of NK-cell developmental and functional programs
    Leong JW, Sullivan RP, Fehniger TA
    Eur J Immunol 2014 Oct;44(10):2862-8
  • Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer
    Romee R, Leong JW, Fehniger TA
    Scientifica (Cairo) 2014;2014:205796
  • Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells.  Biol Blood Marrow Transplant 2014; 14: Epub Jan 2014
  • Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways.  J Immunol 2013;191:5904 Epub Nov 2013
  • Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, Dipersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.             Biol Blood Marrow Transplant 2014;20:46
  • Sullivan RP, Leong JW, Fehniger TA
    MicroRNA regulation of natural killer cells.
    Front Immunol 2013;4:44
  • Leong JW, Sullivan RP, Fehniger TA Natural killer cell regulation by microRNAs in health and disease. J Biomed Biotechnol. 2012;2012:632329
  • Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
    Blood 2013 Jan 3;121(1):159-69
  • Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA.  Cytokine activation induces human memory-like NK cells. Blood 2012 120(24):4751-60
  • Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J
    T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Biol Blood Marrow Transplant 2012 Jun;18(6):937-43
  • Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA
    MicroRNA-deficient NK cells exhibit decreased survival but enhanced function.
    J Immunol 2012 Apr 1;188(7):3019-30
  • Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
    Blood 2011 Nov 10;118(19):5119-25
  • Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
    Blood 2011 Feb 10;117(6):1828-33
  • Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER
    Next-generation sequencing identifies the natural killer cell microRNA transcriptome.
    Genome Res 2010 Nov;20(11):1590-604
  • Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, Link DC
    Complete characterization of the microRNAome in a patient with acute myeloid leukemia.
    Blood 2010 Dec 9;116(24):5316-5326
  • Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ
    Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice.
    Leukemia 2010 Sep;24(9):1662-4
  • White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA
    Latent herpesvirus infection arms NK cells.
    Blood 2010 Jun 3;115(22):4377-83
  • Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ
    Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.
    Blood 2010 Mar 4;115(9):1669-77
  • Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ
    Differential expression of granzyme B and C in murine cytotoxic lymphocytes.
    J Immunol 2009 May 15;182(10):6287-97
  • Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
    Blood 2009 Jan 29;113(5):1002-5
  • Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ
    Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.
    Immunity 2007 Oct;27(4):635-46
  • French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
    Chronic lymphocytosis of functionally immature natural killer cells.
    J Allergy Clin Immunol 2007 Oct;120(4):924-31
  • Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ
    Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs.
    Immunity 2007 Jun;26(6):798-811
  • Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ
    Hop cleavage and function in granzyme B-induced apoptosis.
    J Biol Chem 2006 Dec 1;281(48):37130-41
  • Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA
    CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.
    Blood 2003 Apr 15;101(8):3052-7
  • Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
    Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
    Clin Cancer Res 2002 Sep;8(9):2812-9
  • Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA
    In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.
    Blood 2002 Nov 15;100(10):3633-8
  • Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA
    Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect.
    Blood 2002 Sep 15;100(6):1935-47
  • Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ
    Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system.
    Cytometry 2001 Dec 1;45(4):285-93
  • Cooper MA, Fehniger TA, Caligiuri MA
    The biology of human natural killer-cell subsets. [Review]
    Trends Immunol 2001 Nov;22(11):633-40
  • Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA
    Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
    Blood 2001 May 15;97(10):3146-51
  • Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA
    Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
    Eur J Immunol 2001 Mar;31(3):792-801
  • Fehniger TA, Caligiuri MA
    Interleukin 15: biology and relevance to human disease. [Review]
    Blood 2001 Jan 1;97(1):14-32
  • Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA
    Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.
    J Exp Med 2001 Jan 15;193(2):219-31
  • Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA
    Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
    J Clin Invest 2000 Jul;106(1):117-24
  • Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA
    Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo.
    J Immunol 2000 Feb 15;164(4):1643-7
  • Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA
    Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
    J Immunol 1999 Apr 15;162(8):4511-20
  • Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA
    Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.
    Blood 1998 Nov 15;92(10):3647-57
  • Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O’Brien WA, Caligiuri MA
    Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.
    J Immunol 1998 Dec 1;161(11):6433-8
  • Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA
    Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
    Cancer Immunol Immunother 1998 Aug;46(6):318-26
  • Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS
    Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.
    J Immunol 1998 Jul 1;161(1):400-8
  • Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA
    Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
    J Clin Invest 1998 Mar 15;101(6):1373-8
  • Fehniger TA, Carson WE, Mrozek E, Caligiuri MA
    Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
    Blood 1997 Nov 1;90(9):3647-53
  • Carson WE, Fehniger TA, Caligiuri MA
    CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Eur J Immunol 1997 Feb;27(2):354-60
  • Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA
    A potential role for interleukin-15 in the regulation of human natural killer cell survival.
    J Clin Invest 1997 Mar 1;99(5):937-43

Invited Reviews and Book Chapters